ClinicalTrials.gg

Program

Omeprazole

Also written as “Atazanavir/Ritonavir+Omeprazole”, “omeprazole” and “Omeprazole 20 mg”.

Its studies are mostly in Gastroesophageal Reflux · Neoplasms · Laryngopharyngeal Reflux · Heartburn · HIV Infections, led by 13 companies.

Furthest: phase 4, since Mar 18, 200832 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca90 open or runningphase 4since Mar 18, 2008Nov 20, 2005none ahead
Bayer40 open or runningphase 4since Apr 4, 2012May 2, 2008none ahead
Dr. Reddy's Laboratories40 open or runningphase 1since Jan 8, 2010Jan 8, 2010none ahead
Boehringer Ingelheim30 open or runningphase 1since Sep 30, 2014Sep 30, 2014none ahead
GlaxoSmithKline20 open or runningphase 1since Mar 1, 2007Mar 1, 2007none ahead
Procter and Gamble20 open or runningphase 4since Dec 15, 2008Dec 15, 2008none ahead
Sanofi20 open or runningphase 3since Sep 2, 2009Sep 2, 2009none ahead
AbbVie10 open or runningphase 3since Apr 29, 2008Apr 29, 2008none ahead
ascension-health10 open or runningphase 4since Jan 25, 2013Jan 25, 2013none ahead
nekkar-lab-srl11 open or runningno phasesince Oct 14, 2019Oct 14, 2019none ahead
perle-bioscience-inc10 open or runningphase 3since Jan 2, 2013Jan 2, 2013none ahead
pt-kalbe-farma-tbk10 open or runningno phasesince Feb 8, 2023Feb 8, 2023none ahead
SD Biosensor10 open or runningphase 4since Jan 19, 2009Jan 19, 2009none ahead

Also a collaborator on its studies: pt-pharma-metric-labs, parexel, medpace-inc, syreon-corporation, Bausch Health Companies, Ferring Pharmaceuticals and Tanabe Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Nov 20, 2005.

  1. Apr 15, 2011Phase 1 study in HeartburnBayer · NCT01337804 · 50 enrolled
  2. Feb 10, 2012Phase 1 study in Carcinoma, MedullarySanofi · NCT01539655 · 34 enrolled · United States
  3. Apr 4, 2012Phase 4 study in HeartburnBayer · NCT01587885 · 48 enrolled
  4. Jan 2, 2013perle-bioscience-inc's first study: phase 3 study in Diabetes Mellitus, Type 1New to perle-bioscience-incperle-bioscience-inc · NCT01762644
  5. Jan 25, 2013ascension-health's first study: phase 4 study in Laryngopharyngeal RefluxNew to ascension-healthascension-health · NCT01777854 · 6 enrolled · United States
  6. Aug 5, 2013Phase 1 study in Bioequivalence, AUC, Cmax, PharmacokineticsAstraZeneca · NCT01921920 · 54 enrolled · United States
  7. Sep 30, 2014Boehringer Ingelheim's first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT02253875 · 15 enrolled
  8. Jan 20, 2015Phase 1 study in HealthyBoehringer Ingelheim · NCT02345304 · Germany
  9. May 21, 2015Phase 1 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT02453022 · 18 enrolled · United States
  10. Oct 14, 2019nekkar-lab-srl's first study: no phase study in Gastroesophageal RefluxNew to nekkar-lab-srlnekkar-lab-srl · NCT04130659 · 110 planned · Italy, Romania
  11. Jun 8, 2021Phase 1 study in Advanced Solid TumoursAstraZeneca · NCT04959266 · 5 enrolled · United States, Spain
  12. Apr 1, 2022Phase 1 study in HealthyAstraZeneca · NCT05319912 · 18 enrolled · United States
  13. Feb 8, 2023pt-kalbe-farma-tbk's first study: no phase study in Drug UseNew to pt-kalbe-farma-tbkpt-kalbe-farma-tbk · NCT05849883 · 36 enrolled · Indonesia
  14. Feb 14, 2023No phase study in Liver CirrhosisBoehringer Ingelheim · NCT05741385 · 4 enrolled · Germany

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
RabeprazoleruleEisaiphase 466
tegoprazanruleHK inno.Nphase 448
vonoprazanruleTakedaphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

All 32 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05741385Liver Cirrhosis · Germany–CompletedBoehringer IngelheimAug 9, 20244
NCT05849883Drug Use · Indonesia–Completedpt-kalbe-farma-tbkJan 14, 202136
NCT05319912Healthy · United States1CompletedAstraZenecaMay 29, 201418
NCT04959266Advanced Solid Tumours · United States, Spain1TerminatedAstraZenecaJun 1, 20225
NCT04130659Gastroesophageal Reflux · Italy, Romania–Recruitingnekkar-lab-srlDec 31, 2024110
NCT02453022Pulmonary Disease, Chronic Obstructive · United States1CompletedGlaxoSmithKlineJul 31, 201518
NCT02345304Healthy · Germany1WithdrawnBoehringer IngelheimApr 20150
NCT02253875Healthy1CompletedBoehringer IngelheimFeb 200615
NCT01921920Bioequivalence, AUC, Cmax, Pharmacokinetics · United States1CompletedAstraZenecaNov 201354
NCT01777854Laryngopharyngeal Reflux · United States4Terminatedascension-healthJul 20156
NCT01762644Diabetes Mellitus, Type 13Withdrawnperle-bioscience-incMay 20160
NCT01587885Heartburn4CompletedBayerApr 201248
NCT01539655Carcinoma, Medullary · United States1CompletedSanofiSep 201234
NCT01337804Heartburn1CompletedBayerJan 201150
NCT01159145Pharmacodynamics Study · Japan1CompletedAstraZenecaSep 201042
NCT01170182Healthy1CompletedDr. Reddy's LaboratoriesApr 200654
NCT01170169Healthy1CompletedDr. Reddy's LaboratoriesMar 200644
NCT01045642Healthy · India1CompletedDr. Reddy's LaboratoriesDec 200638
NCT01045434Healthy · India1CompletedDr. Reddy's LaboratoriesJan 200762
NCT00971581Pain · Mexico3CompletedSanofiMay 201052
NCT00903448Healthy · United States4CompletedProcter and GambleJun 200940
NCT00825630Helicobacter Pylori Infection · Israel4CompletedSD BiosensorNov 2009123
NCT00808769Normal Healthy Subject Population · United States4CompletedProcter and GambleDec 200830
NCT00765206Gastric Acid3CompletedBayerAug 200860
NCT00674115Gastric Acid3CompletedBayerJun 200860
NCT00669955Helicobacter Infections · United Kingdom3CompletedAbbVieJul 2009440
NCT00641264Laryngopharyngeal Reflux4CompletedAstraZenecaJun 200390
NCT00443170Anemia · Australia1CompletedGlaxoSmithKline90
NCT00402259Gastrointestinal Hemorrhage · China3CompletedAstraZeneca440
NCT00259077Non-Erosive Reflux Disease · Japan3CompletedAstraZenecaJul 2004270
NCT00259051Non-Erosive Reflux Disease · Japan3CompletedAstraZenecaAug 200440
NCT00256737Gastroesophageal Reflux · Denmark, Finland, Norway and more3CompletedAstraZenecaOct 2005219

How it is read

Names in the registry

  • “Omeprazole”, 30 entries
  • “Atazanavir/Ritonavir+Omeprazole”, 4 entries
  • “omeprazole”, 3 entries
  • “Omeprazole 20 mg”, 2 entries
  • “Omeprazole/sodium bicarbonate”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.